UKMF Science
Contents
LRF / UKMF Cytogenetics Database
Meeting Abstracts
- 2nd Scientific Meeting on Bone Disease in Multiple Myeloma
- Clinical Meeting 2002
- Annual Education Meeting 2002
- 4th Annual UK Myeloma Forum Scientific Meeting
Scientific Aims of the UKMF
We aim to promote scientific studies in the area of myeloma with the purpose of improving the treatment of patients in the UK.
In particular we wish to foster the clinical science/trials interface by encouraging the development of trials protocols which collect and analyse biological material from patients entered into trials. Additionally we would seek to encourage all research activity in the field of myeloma and plasma cell biology.
Myeloma Research in the UK
We have asked a number of groups who we knew carry out work on myeloma. A description of their work is laid out below. We would emphasise that these are not the only groups carrying out myeloma research in the UK, and would encourage groups not listed to supply a description of their work for inclusion.
Investigator(s)
|
Project
|
Location
|
Mark Drayson and
Ian MacLennan
|
Central trials laboratory and
Immune regulations
Mark Drayson
http://medweb4.bham.ac.uk/staffprofiles/Printable.aspx?id=272
Ian MacLennan
|
Birmingham
|
Andy Chantry,
Dave Hughes
|
Andy Chantry
– Bone anabolic agents in
myeloma
http://mellanbycentre.dept.shef.ac.uk/members/chantry.htm
Dave Hughes
– understanding bone disease
through morphology
|
Sheffield
|
Roger Owen,
Gordon Cook
|
Roger Owen
– Minimal residual in myeloma
by flow cytometry
http://www.ukmf.org.uk/documents/Roger_Owen.pdf
Gordon Cook
– stem cell transplantation
in myeloma, NCRI MMX, MRC MMXI
|
Leeds
|
Jamie Cavenagh
|
Stem cell transplantation in myeloma, AML/MDS; Anti-angiogenic
therapies in myeloma. NK cell activity during thalidomide therapy.
|
Barts and The London NHS Trust
|
Steve Schey
|
Designing and conducting clinical; Chairman
of the NCRI Myeloma Clinical Trials Committee. He has been Chief Investigator
and Co-investigator for a large number of clinical trials. His research
interests are in multiple myeloma and the bone marrow microenvironment as
potential novel therapeutic targets, and haemopoietic stem cell
transplantation and he leads the Kings College Myeloma Translational Research
Group at the Rayne Institute Denmark Hill
|
King’s College Medical School, London
|
Gareth Morgan,
Faith Davis
|
Gareth
Morgan - Genetic events
involved in switch recombination, clinical trials and prognostic factors
http://www.icr.ac.uk/research/team_leaders/Morgan_Gareth/index.shtml
Faith Davis – targeted approaches to myeloma therapy
|
Institute of
Cancer Research and Royal Marsden Hospital, London
|
Kwee Yong
|
Myeloma biology and the mechanisms of bone
disease.
http://www.uclh.org/OurServices/Consultants/Pages/DrKweeYoung.aspx
|
University
College, London
|
Lyn MaCallum
|
Investigation
of CCN2 ‘osteogenic signalling’ in Multiple Myeloma
|
Plymouth
|
Fiona Ross
|
Cytogenetics in myeloma
|
Wessex Regional
Cytogenetics Unit
|
Graham Jackson,
Mark Velangi
|
Graham
Jackson - Drug resistance in
myeloma, development of long-term bone marrow transplant follow-up clinics,
and the cytokine profile of acute and chronic GVHD
http://www.newcastle-hospitals.org.uk/staff-profiles/12195.aspx
Mark Velangi
Defects of the DNA mismatch repair
system and pathogenesis of PCD's
|
Newcastle
|
LRF / UKMF Cytogenetics Database
The Wessex Regional Genetics Laboratory can accept myeloma samples to attempt karyotyping and FISH analysis for anyone who does not have this service from their local cytogenetics lab.
This service is funded by the Leukaemia Research Fund and so will not cost you anything other than the postage for the samples. Provided we receive an adequate sample we will report the results of FISHing for 13q and also of karyotyping if this is abnormal. We will be gathering data using a number of other FISH probes, but will not be reporting these results at present.
Although we are glad to provide results where possible, this is essentially a research project. We have to be able to correlate cytogenetic factors with other aspects of the disease. We will therefore need basic patient details such as FBC, urea, creatinine, calcium, albumin, LDH, β2m, CRP, type and level of paraprotein, BJP +/- and amount, details of the aspirate and trephine taken at the time of our sample, results of the skeletal survey, along with later details of disease course in a timely manner when requested. We will provide you with forms for registering this data.
N.B. An adequate sample is obviously essential. Preliminary work has shown that the standard size of sample sent for cytogenetics is inadequate for this study, where we need to separate out the plasma cells. We need at least 3ml of marrow with as much as possible from the first pull. Filling up the tube with marrow blood is not helpful! If your patient is sedated it may be possible for you to perform two aspirates, one for morphology and one for cytogenetics.
If you are interested in using this service please phone, fax or e-mail Fiona Ross to give us your details, discuss numbers and notification and to see whether you require transport medium to be sent.
LRF UK Myeloma Forum Cytogenetics Database
Wessex Regional Genetics Laboratory
Salisbury District Hospital
Salisbury
Wilts SP2 8BJ
Tel: 01722 429087 Fax: 01722 338095
Cytogenetics database progress report [as of May 2001].